{"id":"W4283400007","doi":"10.1016/j.esmoop.2022.100520","title":"Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Janssen Pharmaceuticals; National Cancer Institute; Johnson and Johnson; Deciphera Pharmaceuticals; Roche; Bundesministerium für Gesundheit; Exelixis; Meso Scale Diagnostics; Merck; GlaxoSmithKline; Novartis; Pfizer; U.S. Food and Drug Administration; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Melanoma; Gastroenterology; Tyrosine-kinase inhibitor; Metastatic melanoma; Progression-free survival; Oncology; Phases of clinical research; Cancer; Chemotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000565064,0.0002539537,0.0006409831,0.000173793,0.0001721902,0.0002652612,0.0001537159,0.0002654284,0.002190109],"category_scores_gemma":[0.0007261089,0.00008700677,0.0004959511,0.0001598651,0.0001470946,0.0002969905,0.0001531757,0.0008628174,0.0003826281],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003404875,"about_ca_system_score_gemma":0.000284515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002640006,"about_ca_topic_score_gemma":0.0008150777,"domain_scores_codex":[0.9997968,0.00008406102,0.00001722291,0.00002801784,0.00004049356,0.00003332383],"domain_scores_gemma":[0.9997361,0.00007341766,0.0000691259,0.00002483963,0.00002921812,0.00006728405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.07710932,0.008302659,0.05657436,0.001102489,0.001053306,0.001940008,0.0002482417,0.004633112,0.1203048,0.0003520153,0.01331869,0.7150609],"study_design_scores_gemma":[0.06844077,0.3552623,0.4503967,0.0003791937,0.00225363,0.01167194,0.000246904,0.009593413,0.05550579,0.001106781,0.04501814,0.0001243074],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823767,0.008393049,0.0005290523,0.0004809032,0.00004263383,0.0003759854,0.0007280653,0.0001222291,0.00695136],"genre_scores_gemma":[0.9957593,0.001551137,0.0004449755,0.0004187408,0.00007114938,0.0001208347,0.0007580698,0.000009471025,0.0008663148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002190109,"threshold_uncertainty_score":0.007326663,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0238742433378822,"score_gpt":0.3035334139704138,"score_spread":0.2796591706325316,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}